# Effects of the maternal and fetal proteome on birth weight: a Mendelian randomization analysis

Nancy McBride<sup>\*1,2</sup>, Alba Fernández-Sanlés<sup>1,3</sup>, Marwa Al Arab<sup>2</sup>, Tom A. Bond<sup>1,2,11</sup>, Jie Zheng<sup>5,6</sup>, Maria C. Magnus<sup>7</sup>, Elizabeth C. Corfield<sup>1,8,9</sup>, Gemma L Clayton<sup>1,2</sup>, Liang-Dar Hwang<sup>11</sup>, Robin N. Beaumont<sup>10</sup>, David M. Evans<sup>1,4,11</sup>, Rachel M. Freathy<sup>10</sup>, Tom R. Gaunt<sup>1,2</sup>, Deborah A Lawlor<sup>1,2</sup>, Maria Carolina Borges<sup>1,2</sup>

<sup>1</sup>MRC Integrative Epidemiology Unit at the University of Bristol

<sup>2</sup>Population Health Science, Bristol Medical School, University of Bristol

<sup>3</sup>MRC Unit for Lifelong Health and Ageing, University College London

<sup>4</sup>Frazer Institute, University of Queensland, Brisbane, QLD, Australia

<sup>5</sup>Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

<sup>6</sup>Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

<sup>7</sup>Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway <sup>8</sup>Psychiatric Genetic Epidemiology Group, Research Department, Lovisenberg Diaconal Hospital, Oslo, Norway

<sup>9</sup>PsychGen Centre for Genetic Epidemiology and Mental Health, Norwegian Institute of Public Health, Oslo, Norway

<sup>10</sup>Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK

<sup>11</sup>Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia

\*Corresponding author nancy.mcbride@bristol.ac.uk

### 1 Abstract

#### 2 Background

3 Fetal growth is an important indicator of survival, regulated by maternal and fetal genetic and

- 4 environmental factors. However, little is known about the underlying molecular mechanisms.
- 5 Proteins play a major role in a wide range of biological processes and could provide key
- 6 insights into maternal and fetal molecular mechanisms regulating fetal growth.
- 7 Method

8 We used intergenerational two-sample Mendelian randomization to explore the effects of 9 1,139 maternal and fetal genetically-instrumented plasma proteins on birth weight. We used 10 genome-wide association summary data from the Early Growth Genetics (EGG) consortium 11 (n=406,063 with maternal and/or fetal genotype), with independent replication in the 12 Norwegian Mother, Father and Child Cohort Study (MoBa; n=74,932 mothers and n=62,108 13 offspring). Maternal and fetal data were adjusted for the correlation between fetal and 14 maternal genotype, to distinguish their independent genetic effects.

#### 15 Results

16 We found that higher genetically-predicted maternal levels of NEC1 increased birth weight 17 (mean-difference: 12g (95% CI [6g, 18g]) per 1 standard deviation protein level) as did 18 PRS57 (20g [10g, 31g]) and ULK3 (140g [81g, 199g]). Higher maternal levels of Galectin 4 decreased birth weight (-206g [-299g, -113g]). In contrast, in the offspring, higher 19 20 genetically-predicted offspring levels of NEC1 decreased birth weight (-10g [-16g, -5g]), 21 alongside sLeptin R (-8g [-12g, -4g]), and UBS3B (-78g [-116g, -41g]). Higher fetal levels of 22 Galectin\_4 increased birth weight (174g [89g, 258g]). We replicated these results in MoBa, 23 and found supportive evidence for shared causal variants from genetic colocalization 24 analyses and protein-protein network associations.

#### 25 Conclusions

We find strong evidence for causal effects, sometimes in opposing directions, of maternal and fetal genetically-instrumented proteins on birth weight. These provide new insights into maternal and fetal molecular mechanisms regulating fetal growth, involving glucose metabolism, energy balance, and vascular function that could be used to identify new intervention targets to reduce the risk of fetal growth disorders, and their associated adverse maternal and fetal outcomes.

- 32 Keywords: fetal growth, birth weight, proteomics, molecular mechanisms, Mendelian
- 33 randomization, pregnancy, MoBa

### 35 Introduction

Birth weight is a valuable and widely used measure of fetal growth. Healthy fetal growth is 36 37 essential to minimise adverse perinatal health outcomes, including miscarriage, stillbirth, 38 preterm birth and associated neonatal and infant morbidity and mortality (1-7). Large-scale 39 genome-wide association studies (GWAS) have revealed hundreds of genomic regions 40 independently associated with birth weight (2, 3, 8-10). In addition, these GWAS have uncovered a complex interplay between maternal and fetal genomes (8, 9), in which some 41 42 genetic variants have maternal or fetal-specific effects on birth weight, whereas other genetic 43 variants have both maternal and fetal effects, sometimes in opposite directions. Despite 44 these advances in mapping fetal and maternal genetic variants, understanding the molecular 45 mechanisms underpinning fetal growth remains a challenge (6).

46 Proteins play a major role in a wide range of biological processes (11). They are essential for 47 cellular growth and repair, and could provide key insights into maternal and fetal molecular 48 mechanisms regulating fetal growth (10). Mendelian Randomization (MR) is a method which 49 uses genetic variants associated with exposures as instrumental variables, to test the effect 50 of those exposures on human traits and diseases. The method aims to mitigate causal 51 effects being biased due to confounding and reverse causation that may explain 52 conventional observational associations. Previous MR studies have established causality of 53 maternal modifiable factors on offspring birth weight, including higher maternal adiposity and 54 higher maternal circulating glucose levels on higher birth weight, and smoking and higher 55 blood pressure on lower birth weight (12) (13, 14) (5) (15). They have also provided novel 56 insights, such as a potential effect of higher maternal glutamine levels on higher birth weight 57 (5) and metabolically favourable adiposity on lower birth weight (16). As such, MR and 58 proteomics can be integrated to explore maternal and fetal proteins regulating fetal growth 59 by using genetic variants associated with protein levels (i.e., protein quantitative trait loci -60 pQTL) as instrumental variables. As most drug targets are proteins, identifying the effects of 61 maternal circulating proteins on birth weight could identify targets for drug development that 62 might prevent fetal growth restriction and over-growth, and their associated adverse 63 pregnancy and perinatal outcomes.

The aim of this study was to identify causal effects of maternal and fetal proteins on birth weight to highlight underlying molecular mechanisms. To achieve that, we used two-sample MR, in which large-scale GWAS of plasma proteomics and birth weight were combined to examine the causal effect of plasma proteins on offspring birth weight.

68

#### 69 Methods

We performed a two-sample MR study to identify maternal and fetal effects of plasma 70 proteins on offspring birthweight, examining both maternal and fetal genetic effects 71 72 (n=406,063 with maternal and/or fetal genotype). For proteins passing multiple testing 73 correction (FDR p-value < 5%), we tested whether results replicated in an independent sample (n=74,932 mothers and n=62,108 offspring) and investigated whether MR results 74 75 could be confounded by linkage disequilibrium using genetic colocalization. For proteins 76 which had discovery and replication evidence, and no evidence against colocalization, we 77 used protein network associations to examine plausible pathways through which they could be influencing birth weight. Figure 1 summarises the analytical workflow used in this paper. 78



80

Figure 1 – Schematic representation of the analyses conducted in this paper. Abbreviations:
 GWAS, genome wide association studies; pQTL, protein quantitative trait loci

83

84 Selection of genetic instruments for plasma proteins

We selected genetic instruments from the deCODE GWAS of plasma proteins, which provides data on 4,459 unique proteins, mapped to 13,514 pQTL. For our analyses, we excluded trans instruments (N=2,647 proteins with 6,402 trans pQTL) and secondary variants (N=5,238 secondary pQTL) retaining 1,783 cis pQTL defined as all those within  $\pm 1$  Mb) for 1,812 proteins (P < 1 × 10<sup>-7</sup>) (Supplementary Figure 1)

90 Discovery sample

91

We used publicly available meta-analysed GWAS summary data on birth weight. These data were obtained from the 2019 Early Growth Genetics (EGG) consortium plus UK Biobank (UKBB) GWAS. This GWAS has publicly available estimates of maternal genetic associations adjusted for fetal genotype and fetal genetic associations adjusted for maternal genotype (see below 'Adjustment for maternal/offspring genotype').

97 The following exclusions were made prior to running the GWAS: i) twins and other multiple 98 births, ii) offspring born earlier than 37 weeks of gestation, iii) extreme birth weight outliers 99 (only individuals born between 2.2kg and 4.6kg were included in the maternal GWAS, and 100 individuals born between 2.5 and 4.5kg were included in the offspring GWAS) and iv) babies 101 born with congenital anomalies (for the maternal genotype only). Genetic associations with 102 birth weight were reported by the GWAS in standard deviation (SD) units. We multiplied 103 these by 551.36 (the SD of birth weight in the UKB) to obtain results in grams (g).

Overall, N=406,063 participants contributed to the models estimating the maternal and fetal genetic effects on birth weight that were adjusted, respectively, for fetal and maternal genotype. These included N=101,541 participants who reported their own birth weight and birth weight of their first child, N=195,815 participants with their own birth weight (fetal GWAS), and N=108,707 female participants with data on offspring birth weight (maternal GWAS)(8) (17).

110 Replication study

111

112 For independent replication, we used genetic association data for birth weight from MoBa, a 113 population-based pregnancy cohort study conducted by the Norwegian Institute of Public 114 Health. Pregnant women and their partners were recruited from all over Norway from 1999-115 2008. The women consented to participate in 41% of the pregnancies. The cohort includes 116 approximately N=114,500 children, N=95,200 mothers, and N=75,200 fathers (18). The 117 current study uses version 12 of the quality-assured genetic data files released for research 118 in January 2019. Birthweight was obtained from linked clinical records held in Medical Birth 119 Registry of Norway (MBRN, a national health registry established in 1967 that contains information about all births in Norway, which is linked to the MoBa study using unique 120 121 personal identification numbers). Questionnaire responses from mothers and fathers data 122 were used to identify sex registered at birth, year of birth, birth weight, and multiple births 123 (only available in the offspring). As in the discovery GWAS, multiple births and extremes of 124 birth weight were excluded. Analyses were adjusted for principal components (PCs) and 125 genotyping batch.

126 In MoBa, plasma blood samples were obtained from both parents during pregnancy, and 127 from umbilical cord at birth (19). This project used MoBa genetic data that was quality 128 controlled and imputed using the MoBaPsychGen pipeline, which has previously been 129 described (20). Phasing and imputation were performed using the publicly available 130 Haplotype Reference Consortium release 1.1 panel as a reference (21). The pipeline output 131 consists of best-guess hard-call genotype data for 6,981,748 variants in 207,409 MoBa 132 participants of European ancestry. GWAS in MoBa were run using regenie software (v 3.1.2) 133 on the TSD server (22).

134 Adjustment for maternal/offspring genotype

136 Birth weight is influenced by both maternal and fetal genotype. Therefore, to distinguish 137 maternal and fetal genetic effects, in the discovery GWAS a weighted linear model was used 138 to estimate maternal genetic associations (adjusted for fetal genotype), and fetal genetic 139 associations adjusted for maternal genotype (3). From this, genetically-instrumented 140 maternal effects of proteins on birth weight (not mediated or biased due to horizontal 141 pleiotropy via fetal effects) and genetically instrumented fetal effects of proteins on birth 142 weight (not confounded by maternal genotype) can be estimated. For our discovery sample 143 (EGG+UKB GWAS), we downloaded these adjusted estimates from the GWAS consortium 144 website. For our replication sample (MoBa), we estimated adjusted associations using the 145 weighted linear model implemented via the DONUTS software package (51). As part of this, 146 we used genetic covariance intercepts from LD score regression (LDSC) to account for 147 overlap between maternal and fetal GWAS sample (23). The summary maternal adjusted for 148 fetal, and fetal adjusted for maternal results were then used in our replication two-sample 149 MR.

150 Two sample MR

151

135

152 We conducted MR analyses to study the causal effects of circulating maternal and fetal 153 proteins on birth weight. All MR analyses were performed using the TwoSampleMR R 154 package version 0.5.6 (26). We used the Wald ratio estimator for analyses as only one pQTL 155 was available per protein. Prior to MR analysis, genetic association data for proteins and 156 birth weight were harmonized so that the effect of each genetic variant on the exposure and 157 outcome were relative to the same effect allele. In some instances, data could not be 158 harmonised (due to being palindromic SNPs, A/T or G/C, with allele frequencies close to 159 50%), and these pQTL and their corresponding proteins were removed from further analyses 160 (Supplementary Table 2). After excluding pQTL that failed harmonisation, we retained data 161 for 1,139 proteins instrumented by the same number of cis pQTL (Figure 1 and 162 Supplementary Figure 1). We then analysed maternal and fetal data separately. MR results

with a FDR-adjusted p-value ≤0.05 were carried forward to the replication MR and
 subsequent analyses.

165 We sought replication of the discovery MR results using genetic association data for birth 166 weight from MoBa participants. There is no overlap between the discovery and replication 167 participants. The same procedures for data harmonisation and two-sample MR analyses 168 described in the discovery stage were used in the replication analyses. To report MR results 169 as the mean difference in birth weight (g) per 1 SD increase in protein level, we multiplied 170 MR effect estimates and standard error by 565.63 (g), which corresponds to 1 SD of birth 171 weight in MoBa. We then conducted a fixed effects meta-analysis of estimates from 172 discovery and replication samples using the meta R package (version 6.5-0). Our criteria for 173 replication were: i) directionally consistent results between discovery and replication, ii) 174 associations with a p-value threshold <0.05 in the meta-analysis, as commonly used in 175 GWAS, and reflecting the relatively modest size of the replication sample in comparison to 176 the main analysis sample and (iii) there was no strong evidence supporting heterogeneity 177 between discovery and replication MR estimates (Cochrane's Q p-value > 0.05).

#### 178 Genetic colocalization

179

180 We undertook genetic colocalization analyses using the coloc R package (24) to investigate 181 whether our MR findings were compatible with a shared causal variant or confounded by 182 linkage disequilibrium (LD) (24). This could happen if a selected pQTL is in LD with another 183 genetic variant influencing birth weight via another biological mechanism. Coloc computes 184 all possible configurations of causal variants for each of two traits and uses a Bayesian 185 approach to calculate support for each causal model ( $H_0$ : no association;  $H_1$ : association with protein only; H<sub>2</sub>: association with birth weight only; H<sub>3</sub>: both traits owing to distinct 186 187 causal variants; H<sub>4</sub>: both traits owing to a shared causal variant). We restricted the analyses 188 to a ±500kb window around the pQTL, and assumed a prior probability that any pQTL in the region is associated with the protein only ( $p_1$ ) of 1 × 10<sup>-4</sup>, birth weight only ( $p_2$ ) of 1 × 10<sup>-4</sup>, or 189 both traits  $(p_{12}) 1 \times 10^5$ . We considered a posterior probability of association (PPA) for H<sub>4</sub> > 190 191 0.70 to provide strong evidence for colocalization, while a PPA for  $H_3 > 0.5$  was considered 192 as evidence against colocalization. To facilitate visualisation of genomic signals in each 193 region, we generated stacked recombination plots using the locuscompareR R package 194 (http://locuscompare.com/) (25).

Where available, we extracted genetic association data for the genomic regions selected for colocalization analyses for plasma proteins and birth weight using the IEU Open GWAS (<u>https://gwas.mrcieu.ac.uk/</u>). The summary statistics for the genetic associations were downloaded from the deCODE website https://www.decode.com/summarydata/.

#### 199 Fetal expression lookup

200

201 One of the assumptions of MR is that the genetic instruments are statistically strongly 202 associated with the phenotype in the population to which inference would be made (i.e. the 203 relevance assumption). We were unable to determine whether our genetic instruments 204 associated with fetal (in utero) circulating proteins, due to the absence of large-scale 205 datasets with both offspring genetic data and cord-blood measures of circulating proteins. 206 Instead, we explored whether the proteins with evidence from discovery and replication were 207 expressed in fetal tissue. We used the single-cell transcriptomics data from the human cell 208 atlas of fetal gene expression (26). The atlas was developed from 121 human fetal samples 209 (post-conceptional age = 72-129 days) from 15 organs (eye, heart, intestine, kidney, liver, 210 lung, muscle, pancreas, placenta, spleen, stomach, thymus, adrenal, cerebellum and 211 cerebrum), profiling 4 million single cells using a sci-RNA-seq3 protocol. The authors used a 212 clustering approach building on a form of principal components analysis (uniform manifold 213 approximation and projection - UMAP) to generate a resource where fetal gene expression 214 can be mapped across different organs, tissues and cell types 215 (https://descartes.brotmanbaty.org/). We used this resource to check that our proteins of 216 interest were expressed in fetal tissue, as a further line of evidence.

217

#### 218 Protein networks

219 We explored information on protein-protein associations (referred to as interactions in 220 genetic research) from the STRING database (https://string-db.org/cgi) to gain insights into 221 presumed biological processes underlying our findings. STRING collates information from all 222 known protein-protein interactions databases and provides a visual network of predicted 223 associations for a particular group of proteins, whereby the proteins are represented as 224 'nodes' and the lines which join them are the predicted functional associations. The colour of 225 the line denotes the source of the interaction information (see figure legend) (27). We set the 226 confidence score of a given association to be 'high confidence' and restricted to associations 227 from curated databases (either KEGG, Reactome, BioCyc and Gene Ontology, as well as 228 legacy datasets from PID and BioCarta), experimentally determined (where evidence comes 229 from lab experiments), reported from gene fusions (from reported gene fusion events), gene 230 co-occurrence (where gene families have similar occurrence patterns across genomes), co-231 expression (where gene are shown to be correlated in expression across a large number of 232 datasets) and protein homology (where proteins may have similar structures).

### 234 **Results**

235 Identifying causal effects of maternal circulating proteins on offspring birth weight

We found evidence of causal effects of 5 maternal proteins (instrumented by 5 cis-pQTLs)
on offspring birth weight that passed our 5% false discovery rate (FDR) adjusted p-value
(Figure 2). We found evidence that higher NEC1 increased birth weight (mean-difference:
12g (95% CI: 6g, 18g) per 1 standard deviation protein level) as did PRS57 (20g (10g, 31g))
and ULK3 (140g (81g, 199g)). Higher maternal levels of Galectin\_4 decreased birth weight (206g (-299g, -113g)), as did PTN9 (-159g (-237g, -82g)). (Figure 2).





Figure 2 – Two sample MR results using maternal cis pQTLs against offspring birth weight.
 FDR corrected p-values transformed to their -log10. Results plotted in green passed 5%
 FDR corrected p-value threshold. Abbreviations: SD, standard deviation

247

MR results for maternal proteins NEC\_1, Galectin\_4, ULK3 and PTN9 identified in discovery analyses met our replication criteria based on meta-analysed results from pooled discovery and replication. However, the replication result for PRS57 was not directionally consistent and there was evidence of high heterogeneity in the meta-analysis for PRS57, ULK3, PTN9 (**Figure 3** and **Supplementary Table 6 and 8**).



254

255 Figure 3 Mendelian randomization results estimating the effect of genetically instrumented 256 maternal proteins (in standard deviation units) on offspring birth weight (in grams) in the 257 discovery (orange dots N=210,248 mothers), replication (red dots; N=87,651 mothers) and 258 meta-analysed discovery and replication data. Replication was tested for proteins passing 259 FDR-corrected p-value <0.05 in the discovery data. Our criteria for replication were: i) 260 directionally consistent results between discovery and replication, ii) associations with a p-261 value threshold <0.05 in the meta-analysis, as commonly used in GWAS, and reflecting the 262 relatively modest size of the replication sample in comparison to the main analysis sample 263 and (iii) there was no strong evidence supporting heterogeneity between discovery and 264 replication MR estimates (Cochrane's Q p-value > 0.05).

265

For maternal effects, we undertook colocalization analysis for all proteins which passed our FDR-adjusted p-value in the discovery analysis. For colocalization analyses, results are shown in **Table 1** as posterior probabilities (PP) of no association ( $H_0$ ), association with protein only ( $H_1$ ), birth weight only ( $H_2$ ), both traits owing to distinct causal variants ( $H_3$ ), or

- both traits owing to a shared causal variant (H<sub>4</sub>) (24). The colocalization analyses supported
- 271 causal effects for maternal circulating NEC1, Galectin 4 and PRS57 with offspring birth
- weight, with high H<sub>4</sub> of 0.82, 0.84, and 0.76 respectively (Table 1). For PTN9 and ULK3,
- there was strong evidence that the association stemmed from distinct causal variants.
- 274 **Table 1** Genetic colocalization results for maternal proteins with birth weight

| Protein    | H₀ | H <sub>1</sub> | H <sub>2</sub> | H <sub>3</sub> | H <sub>4</sub> |
|------------|----|----------------|----------------|----------------|----------------|
| NEC1       | 0  | 0.05           | 0              | 0.13           | 0.82           |
| Galectin_4 | 0  | 0.06           | 0              | 0.10           | 0.84           |
| PTN9       | 0  | 0              | 0              | 0.99           | 0              |
| ULK3       | 0  | 0              | 0              | 0.93           | 0.06           |
| PRS57      | 0  | 0.21           | 0              | 0.03           | 0.76           |

Abbreviations – PP, posterior probabilities; H, hypothesis. Results are expressed as posterior probabilities (PP) of no association (H0), association with protein only (H1), birth weight only (H2), both traits owing to distinct causal variants (H3), or both traits owing to a shared causal variant (H4).

Maternal discovery and replication MR, and colocalization results of are summarised in **Table 2.** Together these provide strong evidence for maternal circulating proteins Galectin\_4 and NEC1 being identified in discovery, replication, and not being biased due to confounded by LD (H<sub>4</sub> 0.84 and 0.82, respectively). There was statistical support for PRS57 in the discovery and colocalization analysis (H<sub>4</sub> 0.76), but not the replication. Whilst there was good replication for ULK3, colocalization results for ULK3 and PTN9 suggested results were being driven by distinct causal variants (H<sub>3</sub> > 0.9).

286

287

288

- 289
- 290
- 291
- 292
- 293
- 294

Public

| 295 | Table 2 – Summary of results from analyses exploring the effect of maternal proteins on |
|-----|---|
| 296 | offspring birth weight  |

| Protein    | Uniprot ID | Discovery MR<br>direction of effect | Independently<br>replicated | Colocalization |
|------------|------------|-------------------------------------|-----------------------------|----------------|
| NEC1       | P29120     | +                                   | Yes                         | Yes            |
| Galectin_4 | P56470     | -                                   | Yes                         | Yes            |
| PTN9       | Q99952     | -                                   | Yes                         | No             |
| ULK3       | Q6PHR2     | +                                   | Yes                         | No             |
| PRS57      | Q6UWY2     | +                                   | No                          | Yes            |

297

299

298 Identifying causal effects of fetal circulating proteins on offspring birth weight

We found evidence of causal effects of 14 proteins on offspring birth weight. Higher genetically-predicted offspring levels of NEC1 decreased birth weight (-10g (-16g, -5g), alongside sLeptin\_R (-8g (-12g, -4g)), UBS3B (-78g (-116g, -41g)), FUT5 (-19g (-29g, -9g)), IFN\_a\_b\_R1 (-53g (-84g, -23g)), TWEAK (-24g, (-37g, -11g)) and MK13 (-69g (-108g, -30g)). Higher fetal levels of Galectin\_4 increased birth weight (174g (89g, 258g)), alongside ACADV (227g (142g, 311g)), PLCG1 (133g (72g, 193g)), BCMA (61g (27g, 96g)) Cystatin C (37g (16g, 58g), and FKB1B (46g (26g, 67g)) (**Figure 4**).



Figure 4 – Fetal two sample MR results for cis pQTL. FDR corrected p-values transformed
 to their -log10. Results plotted in green passed FDR corrected p-value threshold.
 Abbreviations: SD, standard deviation

311

312 As in the maternal effects analysis, we conducted replication in MoBa and then ran a meta-313 analysis. We found meta-analysed MR results consistent with discovery for NEC1, 314 Galectin\_4, sLeptin\_R, TWEAK, ACADV, UBS3B, BCMA (same direction of effect and with a 315 meta-analysed FDR adjusted pvalue <0.05 and no evidence of between discovery and replication results heterogeneity). PLCG1, MK13, FUT5, FKB1B, and Cystatin\_c did not 316 317 replicate, and the replication sample estimate had the opposite direction of effect to the 318 discovery sample (Figure 5 and Supplementary Table 7). The pQTL for protein 319 IFN\_a\_b\_R1 was not in our replication data so could not be tested or meta-analysed 320 (Supplementary Table 9).



322 Figure 5 Mendelian randomization analyses estimating the effect of genetically-instrumented 323 fetal proteins (in standard deviation units) on offspring birth weight (in grams) in the 324 discovery (N=297,356 offspring, orange dots), replication (N=62,108 offspring, red dots) and 325 meta-analyses (blue dots) of discovery and replication samples. Replication was tested for 326 proteins passing FDR-corrected p-value <0.05 in the discovery data. Our criteria for 327 replication were: i) directionally consistent results between discovery and replication, ii) 328 associations with a p-value threshold <0.05 in the meta-analysis, as commonly used in 329 GWAS, and reflecting the relatively modest size of the replication sample in comparison to 330 the main analysis sample and (iii) there was no strong evidence supporting heterogeneity 331 between discovery and replication MR estimates (Cochrane's Q p-value > 0.05).

332

333 For fetal effects, we undertook colocalization analysis for all proteins which passed our FDR

adjusted p-value in the discovery analysis. There was strong evidence of colocalization for

NEC1, ACADV, PLCG1, FUT5, IFN a b R1, AIF1L and UBS3B (all  $H_4 > 0.75$ ). There was

moderate evidence of colocalization for sLeptin\_R ( $H_4$  0.65). There was evidence that the

337 MR results for fetal Galectin\_4, Cystatin-C, BCMA and MK13 might be explained by LD

- confounding ( $H_3 > 0.5$  or high  $H_1$ ) (**Table 3**).
- 339 **Table 3** Genetic colocalization results for offspring proteins with birth weight.

| Protein    | H₀ | H <sub>1</sub> | H <sub>2</sub> | H <sub>3</sub> | H <sub>4</sub> |
|------------|----|----------------|----------------|----------------|----------------|
| NEC1       | 0  | 0.14           | 0              | 0.09           | 0.77           |
| Galectin_4 | 0  | 0.07           | 0              | 0.57           | 0.35           |
| ACADV      | 0  | 0              | 0              | 0.16           | 0.83           |
| CystatinC  | 0  | 0.42           | 0              | 0.08           | 0.49           |
| BCMA       | 0  | 0.45           | 0              | 0.09           | 0.45           |
| TWEAK      | 0  | 0              | 0.6            | 0.37           | 0              |
| FUT5       | 0  | 0.09           | 0              | 0.01           | 0.88           |
| FKB1B      | 0  | 0              | 0              | 0.99           | 0              |
| PLCG1      | 0  | 0.03           | 0              | 0.09           | 0.86           |
| MK13       | 0  | 0.33           | 0              | 0.3            | 0.37           |
| IFN_a_b_R1 | 0  | 0.1            | 0              | 0              | 0.89           |
| AIF1L      | 0  | 0.07           | 0              | 0              | 0.93           |
| UBS3B      | 0  | 0.05           | 0              | 0.01           | 0.92           |
| sLeptin_R  | 0  | 0.03           | 0              | 0.3            | 0.65           |

340 Abbreviations - PP, posterior probabilities; H, hypothesis. Results are expressed as

341 posterior probabilities (PP) of no association (H0), association with protein only (H1), birth

weight only (H2), both traits owing to distinct causal variants (H3), or both traits owing to a shared causal variant (H4).

- 345 Fetal discovery and replication MR, and colocalization results of are summarised in Table 4.
- Together these provide strong evidence for fetal circulating proteins.
- 347

| Protein    | Uniprot ID | Discovery MR<br>direction of effect | Independently<br>replicated | Colocalization |
|------------|------------|-------------------------------------|-----------------------------|----------------|
| NEC1       | P29120     | -                                   | Yes                         | Yes            |
| Galectin_4 | O00214     | +                                   | Yes                         | No             |
| ACADV      | P49748     | +                                   | Yes                         | Yes            |
| CystatinC  | P01034     | +                                   | No                          | No             |
| BCMA       | Q02223     | +                                   | No                          | No             |
| TWEAK      | O43508     | -                                   | Yes                         | No             |
| FUT5       | Q11128     | -                                   | No                          | Yes            |
| FKB1B      | Q96AY3     | +                                   | No                          | No             |
| PLCG1      | P19174     | +                                   | No                          | Yes            |
| MK13       | Q92910     | -                                   | No                          | No             |
| IFN_a_b_R1 | P14787     | -                                   | NA                          | Yes            |
| AIF1L      | Q9H8A1     | +                                   | No                          | Yes            |
| UBS3B      | Q8WUW0     | -                                   | Yes                         | Yes            |
| sLeptin_R  | P48357     | -                                   | Yes                         | Uncertain      |

348

349 Fetal expression lookup

350

As a sanity check of our fetal results, we were able to check whether these genes are expressed in fetal tissue using an atlas of human gene expression during development (https://descartes.brotmanbaty.org/). We wanted to see if tissue expression data supported expression of the proteins with evidence from discovery and replication or colocalization in fetal tissue. We found this was the case for genes encoding NEC1 (in pancreas), FUT5 (in lung and thymus), Galectin\_4, UBS3B, sLeptin\_R, AIF1L, PLCG1, IFN\_a\_b\_R1 and ACADV (all expression all across multiple tissues) (**Supplementary Figures 20-29**).

358 Protein networks of identified maternal and fetal proteins affecting birth weight

We undertook protein-protein association analyses for the proteins that replicated in the MR results, and had supporting colocalization results in either maternal (NEC1, Galectin\_4) or fetal analyses (NEC1, ACADV, UBSH3B).

We found evidence that NEC1 (proprotein convertase 1, the same enzyme as PCSK1, as in the **Figure 6B** below) associates with proteins regulating glucose homeostasis, such as

364 insulin (INS), and glucagon (GCG) - hormones produced by the pancreas to regulate blood 365 sugar levels. NEC1 is a stimulator of INS (28, 29). It also associates with proteins regulating 366 food intake, such as pro-opiomelanocortin (POMC) and ghrelin (GHRL) (28-31) (Figure 6B). 367 UBS3B associated with EGFR (part of the epidermal growth factor family), CBL (critical for 368 cell signalling pathways), and UBC (which helps regulate cell stress) (Figure 6C). ACADV 369 had the largest network of associations, including many proteins associated with fatty acid 370 metabolism (ACOX1, CPT2, and other proteins within the thiolase family (enzymes which 371 break down fatty acids) ACAA1 and ACAA2) (Figure 6A). However, Galectin 4 and PRS57 372 had no protein networks which survived our criteria (high confidence, and from sources 373 detailed in **Figure 6** footnote).



382 **Figure 6** - Protein-protein associations - proteins with evidence from both discovery, 383 replication, and colocazation analyses. Different line colours represent different sources of 384 evidence for these predictions - known associations from curated databases (light blue) and 385 experimentally determined (pink); predicted associations from gene neighbourhood (green), 386 gene fusions (red), gene co-occurrence (dark blue), co-expression, and protein homology 387 (lilac). Associations are for proteins jointly contributing to a shared function, rather than 388 specifically binding to each other. Splice isoforms or post-translational modifications are 389 collapsed, i.e. each node represents all the proteins produced by a single, protein-coding 390 gene locus. The physical distances between two nodes along an edge in a graph have no 391 meaning.

#### 392 **Discussion**

We have used two-sample MR to explore the causal effect of maternal pregnancy and fetal plasma proteins on offspring birth weight. We found evidence of potential causal effects, unlikely to be explained by chance or confounding by LD, for 2 maternal circulating proteins (NEC1, Galectin\_4) and 3 fetal circulating proteins (NEC1, ACADV, and UBS3B). For the remainder of the discussion, we focus mainly on these proteins which had the strongest evidence across all analyses.

#### 399 Proteins with opposing maternal and fetal effects on birthweight

400 Two proteins, NEC1 and Galectin\_4, instrumented by cis-pQTLs, appear to be acting in 401 opposite directions when comparing maternal and fetal MR results. They suggest that more 402 NEC1 from the mother leads to higher birth weight, yet more NEC1 from the fetus leads to 403 lower birth weight – as in the case with insulin and other regulators of fetal growth. This is 404 consistent with previous work showing the role of NEC1 in regulating proinsulin processing 405 (32). Indeed, a new drug (Setmelanotide) being tested to treat obesity is known to perturb 406 PCSK1, because PCSK1 mutations lead to deficient signalling in melanocortin pathways 407 (e.g. because of a lack of  $\alpha$ -MSH). Setmelanotide activates MC4R to restore appetite 408 control, addressing genetic obesity caused by disrupted PCSK1 function (33). This is further 409 evidence that our findings could represent molecular targets for birth weight. The STRING 410 protein-protein associations in this study show this link between NEC1 and insulin (INS) and 411 glucagon (GCG) (Figure 6B), demonstrating this known function in glucose homeostasis. It 412 is important to note that whilst these protein-protein associations show co-expression (which 413 may be downstream of a certain mechanism), they do not always imply interaction. 414 Furthermore, the different sources of evidence are important when interpreting these 415 interaction networks. We did not include text-mining and gene neighborhood interactions in 416 the STRING networks so we could follow the most robust lines of evidence, and set a high 417 confidence threshold. This may explain why we did not identify any associations for some 418 proteins that replicated and were supported by colocalization, or because proteins like 419 Galectin 4 are poorly characterized (27).

420 In our analysis, Galectin\_4 was shown to the opposite direction of effect to NEC1 on birth 421 weight. More Galectin\_4 from the mother leads to lower birthweight and more Galectin\_4 422 from the fetus leads to higher birthweight. Galectin\_4 is part of the Galectin family which 423 binds carbohydrates, lactose and sugars (34). Previous work has shown that the Galectin 424 family of β-galactoside binding proteins are important in modulating diverse developmental 425 processes. They contribute to placentation and regulate maternal immune tolerance (34) and 426 have been previously suggested as biomarkers for adverse pregnancy outcomes like 427 gestational diabetes (35) and infertility (34). Other expression studies have shown the 428 importance of Galectins in pregnancy, and the importance of a maternal-fetal balancing act 429 for ideal pregnancy outcomes. For example, lower levels of fetal expression of Galectins 3, 8 430 and 9 have previously been associated with intrauterine growth restriction (34). However, 431 most of the previous studies of plasma Galectin\_4 concentrations in pregnancy have come 432 from mouse or in vitro models (35). It has not been well characterised either inside or outside 433 of pregnancy, demonstrated by the lack of reported associations from the protein-protein

association models. Our study provides an additional line of evidence of a potential role of
Galectin\_4 in fetal growth however there was a lack of colocalization in the fetal effects
analysis (34).

437 PRS57 had strong evidence in the discovery and colocalization analyses for increasing birth 438 weight, however it was the only protein in the maternal analyses which did not replicate. 439 Whilst other members of the serine protease family (a large family of protein-cleaving 440 enzymes) appear critical in pregnancy (e.g. high levels of other serine protease proteins are 441 associated with preeclampsia (36)), to our knowledge, PRS57 has not been previously 442 linked with birth weight, or other disorders of pregnancy. In contrast, PTN9 and ULK3 had 443 evidence from discovery and replication, but not from colocalization. Unfortunately, we had 444 limited power to explore further bias in MR results due to confounding by LD, but high  $H_3$ 445 results suggest this was down to the traits not sharing the same causal variant, although it 446 could also be related to violations of coloc's assumptions due to multiple causal variants.

447 Proteins with fetal-specific effects on birthweight

UBS3B and ACADV had good evidence from discovery, replication, and colocalization. In our analysis, we found higher UBS3B lowered birth weight. UBS3B is a protein that is not yet well characterised for its role in pregnancy, but known to be associated with cellular processes for mammalian development (37). ACADV (very long-chain acyl-coenzyme A dehydrogenase, also known as VCLAD) catalyses the first step in beta-oxidation of longchain fatty acids to release energy (38).

In our fetal analysis, we found evidence that higher fetal cis-pQTL instrumented sLeptin\_R reduced birth weight. sLeptin\_R has a well-established role in energy metabolism, body weight, and is secreted in fetal tissue and the placenta (39). The strong birth weightassociated locus near *CCNL1* from previous GWAS is also associated with leptin levels in adults, providing orthogonal evidence for a key role of this signalling pathway in fetal growth (40). There was good evidence for replication in our study, however the colocalization results fell slightly short of our threshold (H<sub>4</sub> 0.65, as opposed to 0.70).

461 Strengths and limitations

We have integrated the largest-scale proteomics and birthweight genetic association data to shed light on maternal and fetal molecular mechanisms regulating fetal growth. Furthermore, we have used large scale birth weight data from three large European cohorts (EGG, UK Biobank and MoBa) for our discovery, replication analyses and meta analyses. We have

undertaken sensitivity analyses, including checking for confounding by LD and attempted to
 further explain the underlying biology of our molecular findings.

468 In terms of limitations, our analysis has a limited coverage of the proteome due to the use of 469 GWAS data on plasma proteins. For example, because they are not covered in existing 470 proteomic GWAS, we were unable to assess the effects of two key placental expressed 471 proteins - sFlt-1 and PIGF -, which have biological support for affecting fetal growth, and 472 are now used clinically to predict risk of fetal growth restriction and pre-eclampsia in many 473 countries (41-43). To explore effects of these and potentially other placental proteins we 474 would need large proteomic GWAS of maternal pregnancy and cord-blood proteins. It is also 475 likely that there are additional causal proteins that are not placental-/pregnancy-specific, 476 which might be identified in future, where studies have access to even larger proteomics 477 panels, or using cell- or tissue-specific proteomics.

Another potential limitation is related to epitope effects intrinsic to the proteomic technology. Whilst we aimed to reduce the likelihood of misclassification of protein levels through epitope effects (i.e. differences in antigen recognition, rather than protein levels) we cannot rule out some bias from these effects (44). We removed trans-pQTL and only retained cis-pQTL due to the higher possibility of bias due to pleiotropic mechanisms (45). For each protein we only had one SNP, so methods that have been developed to explore bias due to horizontal pleiotropy are not possible.

In using population level proteomics data, a further limitation is that in the exposure data, whilst we can assume in the maternal analysis that the offspring proteins won't affect the levels of the maternal proteins, in the offspring analysis, the assumption that maternal proteins won't affect offspring proteins may not hold. However, there is no way to directly test this.

490 Furthermore, we have assumed that genetic variants identified in protein GWAS conducted 491 in males and non-pregnant women are similarly associated with circulating proteins in 492 fetuses and pregnant women. Ideally, we would test this in studies that have GWAS data 493 and circulating protein levels in women during pregnancy and cord-blood. However, such 494 data is not currently available or only available in small numbers (for example, there is 495 protein data profiled during pregnancy in the Born in Bradford (BiB) cohort, however the 496 Olink coverage is fewer than 453 proteins in 4000 women, with none of these proteins 497 overlapping with our top hits). However we found evidence that some of the proteins (i.e. 498 NEC1, Galectin\_4) that our MR results suggest affect birth weight, are expressed in fetal 499 tissue, which provides some support for their relevance to pregnancy and fetal intrauterine

500 mechanisms. Additionally, supporting evidence from other studies, where genetic variants 501 are instrumental variables for social, behavioural, and molecular exposures during 502 pregnancy, reveals consistent associations with those identified in GWAS of both women 503 and men. This suggests that the assumption is unlikely to be violated. Significantly, with 504 respect to this paper, we have previously demonstrated that among 89 associations 505 involving genetic instruments for one or more of 9 amino acids, there was substantial 506 consistency between those GWAS results derived in men and non-pregnant women, to 507 outcomes in women only (46). This consistency was also observed in women who were 508 pregnant at the time of amino acid measurement for 67 out of the 89 associations (75%). In 509 the remaining 22 associations where heterogeneity was evident, it was likely attributed to the 510 poor quality of genetic imputation for certain variants in the pregnancy study (46).

#### 511 Conclusions

We found strong evidence for causal effects of several proteins on offspring birth weight across a range of analyses, highlighting proteins with opposing maternal and offspring effects (NEC1, Galectin\_4), and fetal (sLeptin\_R, UBS3B, ACADV) effects. These proteins are involved in multiple biological processes governing glucose homeostasis, energy metabolism, endothelial function and adipocyte differentiation. These findings provide new insights into maternal and fetal molecular mechanisms regulating fetal growth.

### 518 **Abbreviations**

- 519 EGG: Early Growth Genetics consortium
- 520 eQTL: expression quantitative trait loci
- 521 GWAS: genome-wide association study
- 522 LD: linkage disequilibrium
- 523 MoBa: Norwegian Mother, Father and Child Cohort Study
- 524 MR: Mendelian Randomisation
- 525 PP: predicted probability
- 526 pQTL: protein quantitative trait loci
- 527 SNP: single nucleotide polymorphism
- 528 UKBB: UK Biobank

### 529 **Declarations**

# 530 Ethics approval and consent to participate

531 All human research was approved by the relevant institutional review boards and conducted 532 according to the Declaration of Helsinki. Participants of all studies in the Early Growth 533 Genetics (EGG) consortium provided written informed consent. The UK Biobank has 534 approval from the North West Multi-Centre Research Ethics Committee, which covers the 535 United Kingdom. The establishment of the Norwegian Mother Father and Child (MoBa) birth 536 cohort and initial data collection was based on a license from the Norwegian Data Protection 537 Agency and approval from The Regional Committees for Medical and Health Research 538 Ethics. The MoBa cohort is currently regulated by the Norwegian Health Registry Act. The 539 current study was approved by The Regional Committees for Medical and Health Research 540 Ethics (223273).

541 Consent for publication

542 NA

### 543 Availability of data and materials

### 544 Data availability

545 Data on birth weight in our discovery analysis was contributed by the EGG Consortium using 546 the UK Biobank Resource and was downloaded from www.egg-consortium.org. The 547 genotype and phenotype data are available on application from the UK Biobank 548 (http://www.ukbiobank.ac.uk/). Individual cohorts participating in the EGG Consortium should 549 be contacted directly as each cohort has different data access policies. The exposure 550 summary data from which genetic instruments were selected for pQTL are available from 551 EpiGraphDB pQTL browser (<u>https://epigraphdb.org/pqtl</u>). Data from MoBa are available from 552 the Norwegian Institute of Public Health after application to the MoBa Scientific Management 553 Group (see its website https://www.fhi.no/en/op/data-access-from-health-registries-health-554 studies-and-biobanks/data-access/applying-for-access-to-data/ for details).

# 555 Acknowledgments

556 We gratefully acknowledge the participants in the studies, who were directly or indirectly 557 participating, via consortia summary data, contributed to this research. We also are grateful 558 to researchers who made their data open access. The Norwegian Mother, Father and Child

559 Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the 560 Ministry of Education and Research. We are grateful to all the participating families in 561 Norway who take part in this on-going cohort study. We thank the Norwegian Institute of 562 Public Health (NIPH) for generating high-quality genomic data. This research is part of the 563 HARVEST collaboration, supported by the Research Council of Norway (#229624). We also 564 thank the NORMENT Centre for providing genotype data, funded by the Research Council of 565 Norway (#223273), South East Norway Health Authorities and Stiftelsen Kristian Gerhard 566 Jebsen. We further thank the Center for Diabetes Research, the University of Bergen for 567 providing genotype data and performing quality control and imputation of the data funded by 568 the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond 569 Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the 570 University of Bergen, and the Western Norway Health Authorities. This work was carried out 571 using the computational facilities of the Advanced Computing Research Centre, University of 572 Bristol - http://www.bristol.ac.uk/acrc/ and the TSD (Tjeneste for Sensitive Data) facilities, 573 owned by the University of Oslo, operated and developed by the TSD service group at the 574 University of Oslo, IT Department (USIT) (tsd-drift@usit.uio.no). The computations on this 575 platform were performed on resources provided by Sigma2 - the National Infrastructure for 576 High-Performance Computing and Data Storage in Norway.

# 577 Funding

This work was supported by the University of Bristol and UK Medical Research Council ( MC\_UU\_00032/05), the US National Institute for Health (R01 DK10324), the European Research Council via Advanced Grant 101021566, the British Heart Foundation (AA/18/7/34219 and CS/16/4/32482) and the National Institute of Health Research Bristol Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol.

584 RMF and RNB were funded by a Wellcome Trust and Royal Society Sir Henry Dale 585 Fellowship (WT104150). RMF is supported by a Wellcome Senior Research Fellowship 586 (WT220390). This research was supported by the National Institute for Health and Care 587 Research Exeter Biomedical Research Centre. This research was funded in part by the 588 Wellcome Trust [WT220390]. J.Z. is supported by grants from the National Key Research 589 and Development Program of China (2022YFC2505203). MCB is funded by a University of 590 Bristol Vice Chancellor's Fellowship. EC is supported by funding from the Research Council 591 of Norway (#274611) and the South-Eastern Norway Regional Health Authority (#2021045).

- 592 The views expressed in this paper are those of the authors and not necessarily those of the
- 593 any of the funders listed above.
- 594 For open access, the authors have applied a CC BY public copyright licence to any Author
- 595 Accepted Manuscript version arising from this submission.

### 596 Author contributions

597 Study conception: DAL, MCB, RMF; Analysis: NM, MCB; Manuscript drafting: NM; 598 Manuscript revisions: NM, MCB, DAL, AFS, MA, RB, RMF, TB, TRG, JZ, DE, DH, GC, EC, 599 MM

### 600 Conflict of interest

601 The authors report no conflict of interest.

## 602 Code availability

All code is available on the GitHub repo https://github.com/MRCIEU/MR-PREG

### 604 **References**

Küpers LK, Monnereau C, Sharp GC, Yousefi P, Salas LA, Ghantous A, et al. Meta-analysis of
 epigenome-wide association studies in neonates reveals widespread differential DNA methylation
 associated with birthweight. Nature Communications. 2019;10(1):1893.

Leite DFB, Cecatti JG. Fetal Growth Restriction Prediction: How to Move beyond. The
 Scientific World Journal. 2019;2019:1519048.

Warrington NM, Freathy RM, Neale MC, Evans DM. Using structural equation modelling to
jointly estimate maternal and fetal effects on birthweight in the UK Biobank. International Journal of
Epidemiology. 2018;47(4):1229-41.

4. Wilcox AJ. On the importance—and the unimportance— of birthweight. International
Journal of Epidemiology. 2001;30(6):1233-41.

5. Barry CA-O, Lawlor DA, Shapland CA-O, Sanderson E, Borges MA-O. Using Mendelian
Randomisation to Prioritise Candidate Maternal Metabolic Traits Influencing Offspring Birthweight.
LID - 10.3390/metabo12060537 [doi] LID - 537. (2218-1989 (Print)).

Bond TA, Karhunen V, Wielscher M, Auvinen J, Männikkö M, Keinänen-Kiukaanniemi S, et al.
 Exploring the role of genetic confounding in the association between maternal and offspring body
 mass index: evidence from three birth cohorts. International Journal of Epidemiology.
 2019;49(1):233-43.

Find the second s

A Cohort Study of 979,912 Term Singleton Pregnancies in Scotland. PLOS Medicine.

625 2017;14(1):e1002228.

8. Warrington NM, Beaumont RN, Horikoshi M, Day FR, Helgeland Ø, Laurin C, et al. Maternal
and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. Nature
genetics. 2019;51(5):804-14.

629 9. Beaumont RN, Warrington NM, Cavadino A, Tyrrell J, Nodzenski M, Horikoshi M, et al. 630 Genome-wide association study of offspring birth weight in 862577 women identifies five novel loci 631 and highlights maternal genetic effects that are independent of fetal genetics. (1460-2083 632 (Electronic)). 633 10. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al. 634 Large-scale integration of the plasma proteome with genetics and disease. Nature Genetics. 635 2021;53(12):1712-21. 636 Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et al. Phenome-wide 11. 637 Mendelian randomization mapping the influence of the plasma proteome on complex diseases. 638 Nature Genetics. 2020;52(10):1122-31. 639 12. Zhang G, Bacelis J, Lengyel C, Teramo K, Hallman M, Helgeland Ø, et al. Assessing the Causal 640 Relationship of Maternal Height on Birth Size and Gestational Age at Birth: A Mendelian 641 Randomization Analysis. (1549-1676 (Electronic)). 642 13. Tyrrell J, Richmond RC, Palmer TM, Feenstra B, Rangarajan J, Metrustry S, et al. Genetic 643 Evidence for Causal Relationships Between Maternal Obesity-Related Traits and Birth Weight. (1538-644 3598 (Electronic)). 645 Ardissino MA-O, Slob EA-O, Millar O, Reddy RA-OX, Lazzari L, Patel KHK, et al. Maternal 14. 646 Hypertension Increases Risk of Preeclampsia and Low Fetal Birthweight: Genetic Evidence From a 647 Mendelian Randomization Study. (1524-4563 (Electronic)). 648 Brand JA-O, Gaillard RA-O, West JA-O, McEachan RA-O, Wright JA-O, Voerman E, et al. 15. 649 Associations of maternal quitting, reducing, and continuing smoking during pregnancy with 650 longitudinal fetal growth: Findings from Mendelian randomization and parental negative control 651 studies. (1549-1676 (Electronic)). 652 16. Thompson WA-O, Beaumont RA-O, Kuang AA-O, Warrington NA-OX, Ji Y, Tyrrell JA-O, et al. Higher maternal adiposity reduces offspring birthweight if associated with a metabolically 653 654 favourable profile. (1432-0428 (Electronic)). 655 Allen NE, Sudlow C, Peakman T, Collins R, Biobank UK. UK biobank data: come and get it. Sci 17. 656 Transl Med. 6. United States2014. p. 224ed4. 657 Haugan A, Birke C, Alsaker E, Høiseth G, Knudsen GP, Tambs K, et al. Cohort Profile Update: 18. 658 The Norwegian Mother and Child Cohort Study (MoBa). International Journal of Epidemiology. 659 2016;45(2):382-8. 660 19. Paltiel L, Anita H, Skjerden T, Harbak K, Bækken S, Nina Kristin S, et al. The biobank of the 661 Norwegian Mother and Child Cohort Study – present status. Norsk Epidemiologi. 2014;24(1-2). 662 20. Corfield EC, Frei O, Shadrin AA, Rahman Z, Lin A, Athanasiu L, et al. The Norwegian Mother, 663 Father, and Child cohort study (MoBa) genotyping data resource: MoBaPsychGen pipeline v.1. 664 bioRxiv. 2022:2022.06.23.496289. 665 21. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference 666 panel of 64,976 haplotypes for genotype imputation. Nature Genetics. 2016;48(10):1279-83. 667 22. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. 668 Computationally efficient whole-genome regression for quantitative and binary traits. Nature 669 Genetics. 2021;53(7):1097-103. 670 23. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score 671 regression distinguishes confounding from polygenicity in genome-wide association studies. Nature 672 Genetics. 2015;47(3):291-5. 673 24. Wallace C. Statistical Testing of Shared Genetic Control for Potentially Related Traits. Genetic 674 Epidemiology. 2013;37(8):802-13. 675 25. Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant associations with 676 gene expression complicate GWAS follow-up. Nature Genetics. 2019;51(5):768-9. 677 26. Cao J, O'Day DR, Pliner HA, Kingsley PD, Deng M, Daza RM, et al. A human cell atlas of fetal 678 gene expression. Science. 2020;370(6518):eaba7721.

679 27. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING 680 v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Research. 681 2014;43(D1):D447-D52. 682 28. Benzinou M, Creemers Jw Fau - Choquet H, Choquet H Fau - Lobbens S, Lobbens S Fau - Dina 683 C, Dina C Fau - Durand E, Durand E Fau - Guerardel A, et al. Common nonsynonymous variants in 684 PCSK1 confer risk of obesity. (1546-1718 (Electronic)). 685 Stijnen P, Ramos-Molina B, O'Rahilly S, Creemers JWM. PCSK1 Mutations and Human 29. 686 Endocrinopathies: From Obesity to Gastrointestinal Disorders. Endocrine Reviews. 2016;37(4):347-687 71. 688 30. Wei X, Ma X, Lu R, Bai G, Zhang J, Deng R, et al. Genetic Variants in PCSK1 Gene Are 689 Associated with the Risk of Coronary Artery Disease in Type 2 Diabetes in a Chinese Han Population: 690 A Case Control Study. PLOS ONE. 2014;9(1):e87168. 691 31. Gjesing AP, Vestmar MA, Jørgensen T, Heni M, Holst JJ, Witte DR, et al. The Effect of PCSK1 692 Variants on Waist, Waist-Hip Ratio and Glucose Metabolism Is Modified by Sex and Glucose 693 Tolerance Status. PLOS ONE. 2011;6(9):e23907. 694 Nead KT, Li A, Wehner MR, Neupane B, Gustafsson S, Butterworth A, et al. Contribution of 32. 695 common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a 696 systematic review and meta-analysis with evidence from up to 331 175 individuals. (1460-2083 697 (Electronic)). 698 Ryan DH. Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide 33. 699 and Bimagrumab: What do They Mean for Clinical Practice? J Obes Metab Syndr. 2021;30(3):196-700 208. 701 34. Blois SM, Dveksler G, Vasta GR, Freitag N, Blanchard V, Barrientos G. Pregnancy 702 Galectinology: Insights Into a Complex Network of Glycan Binding Proteins. (1664-3224 (Electronic)). 703 35. Schrader S, Unverdorben L, Hutter S, Knabl J, Schmoeckel E, Meister S, et al. Overexpression 704 of galectin-4 in placentas of women with gestational diabetes. (1872-7603 (Electronic)). 705 Ajayi F, Kongoasa N, Gaffey T, Asmann YW, Watson WJ, Baldi A, et al. Elevated expression of 36. 706 serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion. Am J 707 Obstet Gynecol. 2008;199(5):557.e1-10. 708 Vukojević K, Šoljić V, Martinović V, Raguž F, Filipović N. The Ubiguitin-Associated and SH3 37. 709 Domain-Containing Proteins (UBASH3) Family in Mammalian Development and Immune Response. 710 Int J Mol Sci. 2024;25(3). 711 Pena LD, van Calcar SC, Hansen J, Edick MJ, Walsh Vockley C, Leslie N, et al. Outcomes and 38. 712 genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and 713 enrolled in the IBEM-IS database. Mol Genet Metab. 2016;118(4):272-81. 714 39. Hoggard N, Hunter L, Duncan JS, Williams LM, Trayhurn P, Mercer JG. Leptin and leptin 715 receptor mRNA and protein expression in the murine fetus and  placenta. Proceedings of 716 the National Academy of Sciences. 1997;94(20):11073-8. 717 40. Kilpeläinen TO, Carli JFM, Skowronski AA, Sun Q, Kriebel J, Feitosa MF, et al. Genome-wide 718 meta-analysis uncovers novel loci influencing circulating leptin levels. Nature Communications. 719 2016;7(1):10494. 720 Agrawal S, Cerdeira AS, Redman C, Vatish M. Meta-Analysis and Systematic Review to Assess 41. 721 the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of 722 Preeclampsia: The SaPPPhirE Study. (1524-4563 (Electronic)). 723 42. Andrikos AA-OX, Andrikos D, Schmidt B, Birdir C, Kimmig R, Gellhaus A, et al. Course of the 724 sFlt-1/PIGF ratio in fetal growth restriction and correlation with biometric measurements, feto-725 maternal Doppler parameters and time to delivery. (1432-0711 (Electronic)). 726 Chang Y-S, Chen C-N, Jeng S-F, Su Y-N, Chen C-Y, Chou H-C, et al. The sFlt-1/PIGF ratio as a 43. 727 predictor for poor pregnancy and neonatal outcomes. Pediatrics & Neonatology. 2017;58(6):529-33. 728 Suhre K, McCarthy MI, Schwenk JM. Genetics meets proteomics: perspectives for large 44. 729 population-based studies. Nature Reviews Genetics. 2021;22(1):19-37.

- Fauman EB, Hyde C. An optimal variant to gene distance window derived from an empirical
   definition of cis and trans protein QTLs. BMC Bioinformatics. 2022;23(1):169.
- 732 46. Zhao J, Stewart ID, Baird D, Mason D, Wright J, Zheng J, et al. Causal effects of maternal
- circulating amino acids on offspring birthweight: a Mendelian randomisation study. (2352-3964
- 734 (Electronic)).

# 735 Supplementary

736



737

- 739 Supplementary figure 1 a workflow of instruments (pQTL) used in our analysis.
- 740 Abbreviations: pQTL, protein quantitative trait loci



Supplementary figure 2 - Genetic associations with NEC1 and offspring birth weight 742 in maternal analysis. Each data point represents one genetic variant. The purple 743 diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for strength 744 of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, 745 the plot shows the correlation between log 10 p-values for the genetic association 746 with protein levels (x axis) and birth weight (y axis). The right panels show 747 recombination plots for the protein (top panel) and birth weight (bottom panel) with 748 log10 p-values in the y axis and chromosome positions in the x axis. 749



Supplementary figure 3 - Genetic associations with Galectin\_4 and offspring birth
 weight in maternal analysis. Each data point represents one genetic variant. The
 purple diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for

strength of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, the plot shows the correlation between log 10 p-values for the genetic association with protein levels (x axis) and birth weight (y axis). The right panels show recombination plots for the protein (top panel) and birth weight (bottom panel) with log10 p-values in the y axis and chromosome positions in the x axis.



Supplementary figure 4 - Genetic associations with PRS57 and offspring birth weight 760 in maternal analysis. Each data point represents one genetic variant. The purple 761 diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for strength 762 of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, 763 764 the plot shows the correlation between log 10 p-values for the genetic association with protein levels (x axis) and birth weight (y axis). The right panels show 765 766 recombination plots for the protein (top panel) and birth weight (bottom panel) with 767 log10 p-values in the y axis and chromosome positions in the x axis.



Supplementary figure 5 - Genetic associations with PTN9 and offspring birth weight 769 in offspring analyses. Each data point represents one genetic variant. The purple 770 diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for strength 771 of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, 772 the plot shows the correlation between log 10 p-values for the genetic association 773 774 with protein levels (x axis) and birth weight (y axis). The right panels show 775 recombination plots for the protein (top panel) and birth weight (bottom panel) with log10 p-values in the y axis and chromosome positions in the x axis. 776



Supplementary figure 6 - Genetic associations with ULK3 and offspring birth weight 778 in maternal analysis. Each data point represents one genetic variant. The purple 779 diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for strength 780 of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, 781 the plot shows the correlation between log 10 p-values for the genetic association 782 with protein levels (x axis) and birth weight (y axis). The right panels show 783 recombination plots for the protein (top panel) and birth weight (bottom panel) with 784 785 log10 p-values in the y axis and chromosome positions in the x axis.



Supplementary figure 7 - Genetic associations with NEC1 and offspring birth weight 787 in offspring analysis. Each data point represents one genetic variant. The purple 788 diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for strength 789 of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, 790 the plot shows the correlation between log 10 p-values for the genetic association 791 with protein levels (x axis) and birth weight (y axis). The right panels show 792 recombination plots for the protein (top panel) and birth weight (bottom panel) with 793 794 log10 p-values in the y axis and chromosome positions in the x axis.



786

796 Supplementary figure 8 - Genetic associations with Galectin 4 and offspring birth weight in offspring analysis. Each data point represents one genetic variant. The 797 purple diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for 798 strength of linkage disequilibrium between the genetic variant and the pQTL. In the 799 800 left panel, the plot shows the correlation between log 10 p-values for the genetic 801 association with protein levels (x axis) and birth weight (y axis). The right panels 802 show recombination plots for the protein (top panel) and birth weight (bottom panel) 803 with log10 p-values in the y axis and chromosome positions in the x axis.



Supplementary figure 9 - Genetic associations with Cystatin c and offspring birth 805 weight in offspring analysis. Each data point represents one genetic variant. The 806 purple diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for 807 strength of linkage disequilibrium between the genetic variant and the pQTL. In the 808 809 left panel, the plot shows the correlation between log 10 p-values for the genetic 810 association with protein levels (x axis) and birth weight (y axis). The right panels 811 show recombination plots for the protein (top panel) and birth weight (bottom panel) 812 with log10 p-values in the y axis and chromosome positions in the x axis.



Supplementary figure 10 - Genetic associations with ACADV and offspring birth 814 815 weight in offspring analysis. Each data point represents one genetic variant. The purple diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for 816 817 strength of linkage disequilibrium between the genetic variant and the pQTL. In the 818 left panel, the plot shows the correlation between log 10 p-values for the genetic association with protein levels (x axis) and birth weight (y axis). The right panels 819 820 show recombination plots for the protein (top panel) and birth weight (bottom panel) 821 with log10 p-values in the y axis and chromosome positions in the x axis.



Supplementary figure 11 - Genetic associations with BCMA and offspring birth 823 824 weight in offspring analysis. Each data point represents one genetic variant. The purple diamond represents the selected pQTL. Colours indicate the  $R^2$  values for 825 strength of linkage disequilibrium between the genetic variant and the pQTL. In the 826 827 left panel, the plot shows the correlation between log 10 p-values for the genetic association with protein levels (x axis) and birth weight (y axis). The right panels 828 829 show recombination plots for the protein (top panel) and birth weight (bottom panel) 830 with log10 p-values in the y axis and chromosome positions in the x axis.



Supplementary figure 12 - Genetic associations with TWEAK and offspring birth 832 weight in offspring analysis. Each data point represents one genetic variant. The 833 purple diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for 834 835 strength of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, the plot shows the correlation between log 10 p-values for the genetic 836 837 association with protein levels (x axis) and birth weight (y axis). The right panels 838 show recombination plots for the protein (top panel) and birth weight (bottom panel) with log10 p-values in the y axis and chromosome positions in the x axis. 839



Supplementary figure 13 - Genetic associations with FUT5 and offspring birth weight 841 in offspring analysis. Each data point represents one genetic variant. The purple 842 diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for strength 843 of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, 844 845 the plot shows the correlation between log 10 p-values for the genetic association with protein levels (x axis) and birth weight (y axis). The right panels show 846 recombination plots for the protein (top panel) and birth weight (bottom panel) with 847 848 log10 p-values in the y axis and chromosome positions in the x axis.







Supplementary figure 15 - Genetic associations with PLCG1 and offspring birth 859 weight in offspring analysis. Each data point represents one genetic variant. The 860 purple diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for 861 strength of linkage disequilibrium between the genetic variant and the pQTL. In the 862 left panel, the plot shows the correlation between log 10 p-values for the genetic 863 864 association with protein levels (x axis) and birth weight (y axis). The right panels show recombination plots for the protein (top panel) and birth weight (bottom panel) 865 866 with log10 p-values in the y axis and chromosome positions in the x axis.



Supplementary figure 16 - Genetic associations with MK13 and offspring birth weight 868 869 in offspring analysis. Each data point represents one genetic variant. The purple diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for strength 870 of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, 871 the plot shows the correlation between log 10 p-values for the genetic association 872 873 with protein levels (x axis) and birth weight (y axis). The right panels show recombination plots for the protein (top panel) and birth weight (bottom panel) with 874 875 log10 p-values in the y axis and chromosome positions in the x axis.

876



Supplementary figure 18 - Genetic associations with AIF1L and offspring birth weight 878 in offspring analysis. Each data point represents one genetic variant. The purple 879 diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for strength 880 881 of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, the plot shows the correlation between log 10 p-values for the genetic association 882 883 with protein levels (x axis) and birth weight (y axis). The right panels show recombination plots for the protein (top panel) and birth weight (bottom panel) with 884 885 log10 p-values in the y axis and chromosome positions in the x axis.





Supplementary figure 19 - Genetic associations with sLeptin\_R and offspring birth weight in offspring analysis. Each data point represents one genetic variant. The purple diamond represents the selected pQTL. Colours indicate the R<sup>2</sup> values for strength of linkage disequilibrium between the genetic variant and the pQTL. In the left panel, the plot shows the correlation between log 10 p-values for the genetic association with protein levels (x axis) and birth weight (y axis). The right panels show recombination plots for the protein (top panel) and birth weight (bottom panel) with log10 p-values in the y axis and chromosome positions in the x axis.



....



907

Supplementary figure 20 - Fetal single cell gene expression expressed in the
 pancreas for NEC1, where the organs are shown in yellow and the single cells
 demonstrating expression in navy blue.



911

Supplementary figure 22 - Fetal single cell gene expression expressed tissue-wide
for Galectin\_4, where the organs are shown in yellow and the single cells
demonstrating expression in navy blue.



916

- 917 Supplementary figure 23 Fetal single cell gene expression expressed tissue-wide
- for FUT5, where the organs are shown in yellow and the single cells demonstrating
- 919 expression in navy blue.



- 921 Supplementary figure 24 Fetal single cell gene expression expressed tissue-wide
- for UBS3B, where the organs are shown in yellow and the single cells demonstrating
- 923 expression in navy blue.



924

Supplementary figure 25 - Fetal single cell gene expression expressed tissue-wide
 for sLeptin\_R, where the organs are shown in yellow and the single cells
 demonstrating expression in navy blue.



928

929 Supplementary figure 26 - Fetal single cell gene expression expressed tissue-wide

for AIF1L, where the organs are shown in yellow and the single cells demonstrating expression in navy blue.



932

933 Supplementary figure 27 - Fetal single cell gene expression expressed tissue-wide

for PLCG1, where the organs are shown in yellow and the single cells demonstrating expression in navy blue.



936

Supplementary figure 28 - Fetal single cell gene expression expressed tissue-wide
 for IFN\_a\_b\_R1, where the organs are shown in yellow and the single cells
 demonstrating expression in navy blue.



940

941 Supplementary figure 29 - Fetal single cell gene expression expressed tissue-wide

for ACADV, where the organs are shown in yellow and the single cells demonstrating expression in navy blue.

944

945



Supplementary figure 22 - Fetal single cell gene expression expressed tissue-wide
for sLeptin\_R, where the organs are shown in yellow and the single cells
demonstrating expression in navy blue.